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GSK3-Mediated BCL-3 Phosphorylation
Modulates Its Degradation and Its Oncogenicity
and was originally identified through molecular cloning
of the breakpoint of the t(14;19) chromosome transloca-
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Patrick Viatour,1 Emmanuel Dejardin,4
Michael Warnier,1 Florence Lair,1 Estefania Claudio,5
Fabrice Bureau,2 Jean-Christophe Marine,6
Marie-Paule Merville,1 Ulrich Maurer,4 Douglas Green,4 leukemias (McKeithan et al., 1987). This translocation
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Summary Results
The oncoprotein BCL-3 is a nuclear transcription fac- GSK3 Phosphorylates BCL-3
tor that activates NF-B target genes through forma- In the process of studying BCL-3 expression in leuke-
tion of heterocomplexes with p50 or p52. BCL-3 is mia, we detected multiple forms of the BCL-3 protein
phosphorylated in vivo, but specific BCL-3 kinases in several leukemic samples, therefore suggesting post-
have not been identified so far. In this report, we show translational modifications such as phosphorylation (Vi-
that BCL-3 is a substrate for the protein kinase GSK3 atour et al., 2003a). Because no BCL-3 kinase has been
and that GSK3-mediated BCL-3 phosphorylation, identified so far, we searched for potential candidates
which is inhibited by Akt activation, targets its degra- by first mapping the BCL-3 targeted domain. 293 cells
dation through the proteasome pathway. This phos- were transfected with expression plasmids coding for
phorylation modulates its association with HDAC1, -3, FLAG-tagged wild-type BCL-3, C BCL-3, N BCL-3,
and -6 and attenuates its oncogenicity by selectively or a BCL-3 protein harboring only the ankyrin repeats
controlling the expression of a subset of newly identi- (Figure 1A, lanes 2, 3, 4, and 5, respectively), and cell
fied target genes such as SLPI and Cxcl1. Our results extracts were subjected to anti-FLAG Western analysis.
therefore suggest that constitutive BCL-3 phosphory- Slower migrating forms were detectable for the wild-
lation by GSK3 regulates BCL-3 turnover and tran- type BCL-3 protein as well as for N BCL-3 (Figure 1A,
scriptional activity. lanes 2 and 4), but not for the other BCL-3 mutants
(Figure 1A, lanes 3 and 5). To demonstrate that these
Introduction slower migrating forms are due to phosphorylation, 10
or 20 l of cell extracts from 293 cells transfected with
Constitutive NF-B activation, a hallmark of many hu- FLAG-BCL-3 was left untreated (Figure 1B, lanes 2 and
man cancers, upregulates the expression of antiapo- 4) or incubated with  phosphatase (Figure 1B, lanes 3
ptotic genes and therefore disrupts the balance between and 5). Using both amounts of cell extracts, we observed
apoptosis and proliferation (Karin et al., 2002). In some that the phosphatase treatement led to the disappear-
cases, high NF-B activity in cancer cells results from ance of the slower migrating BCL-3 forms (Figure 1B,
point mutations or translocations of the genes coding compare lanes 2 and 4 with lanes 3 and 5).
for the NF-B or IB proteins, whereas in other cases, To search for BCL-3 kinase, in silico analysis was
mutations have not been described, despite high IKK carried out using the Scansite software (see Experimen-
and NF-B activities (Karin et al., 2002). The BCL-3 pro- tal Procedures). The kinase-accessible surface essen-
tein is a member of the IB family of NF-B inhibitors tially lies at the C-terminal end of the protein, in agree-
ment with the results described in Figure 1A (data not
shown). Several putative phosphorylation sites were*Correspondence: alain.chariot@ulg.ac.be
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Figure 1. BCL-3 Phosphorylation by GSK3
In Vitro
(A) BCL-3 is phosphorylated downstream of
the ankyrin repeats. (Top) Representation of
the wild-type BCL-3 protein and the BCL-3
mutants. Anti-FLAG Western blots were car-
ried out on extracts from 293 cells transfected
with pcDNA3 alone (lane 1) or with the indi-
cated FLAG-tagged wild-type (lane 2) and
BCL-3 mutant expression vectors (C BCL-3,
N BCL-3, and ankyrin domain in lanes 3, 4,
and 5, respectively). The asterisks illustrate
the phosphorylated form of BCL-3.
(B)  phosphatase dephosphorylates ectopi-
cally expressed FLAG-BCL-3. 293 cells were
transfected with an empty vector (lane 1) or
with FLAG-BCL-3 (lanes 2–5). 10 (lanes 2 and
3) or 20 l (lanes 4 and 5) of extracts were
untreated (lanes 2 and 4) or incubated with
400 units of phosphatase (lanes 3 and 5) at
37C for 1 hr and subsequently subjected to
anti-FLAG Western analysis.
(C) Representation of the BCL-3 protein. The
ankyrin repeats (aa 126–329) are shown as
hatched rectangles. The putative BCL-3 ki-
nases and phosphorylated sites as well as
the percentile values are mentioned.
(D and E) BCL-3 is phosphorylated by GSK3
and Erk1 but not by Akt nor CKII in vitro. A
purified GST-BCL-3 fusion protein was incu-
bated with increasing amounts of recombi-
nant GSK3 (D) or active Akt, Erk1, or CKII
(E), and in vitro kinase assays were done.
identified on BCL-3 and included two Erk1 sites as well kinase assay with a purified GST-BCL-3 protein as a
substrate (Figure 2A). Again, a BCL-3 phosphorylationas two distinct GSK3-target residues at S394 and S398
(Figure 1C, top panel). Therefore, BCL-3 is phosphory- was detected with the anti-GSK3, but not with the anti-
HA, immunoprecipitates (Figure 2A).lated on its C-terminal domain, downstream of the an-
kyrin repeats, as previously suggested (Bundy and Mc- To further demonstrate that GSK3 phosphorylates
BCL-3, 293 cells were transfected with an empty vectorKeithan, 1997).
To determine whether BCL-3 is phosphorylated by or FLAG-BCL-3 (Figure 2B, left panels, lanes 1 and 2–5,
respectively) and subsequently left untreated (Figure 2B,GSK3, recombinant GSK3 kinase was incubated with
purified GST-BCL-3 protein. A strong dose-dependent left panels, lanes 1 and 2) or incubated with increasing
concentrations of LiCl, a specific GSK3 inhibitor (Figuresignal was detected (Figure 1D). Because phosphoryla-
tion by GSK3 needs to be primed by a prior phosphoryla- 2B, left panels, lanes 3–5). Anti-FLAG Western analysis
performed on the cell extracts indicated that LiCl treat-tion mediated by another kinase, in most cases CKII, we
investigated whether this latter kinase phosphorylates ment led to a dose-dependent decrease of the BCL-3
slower migrating forms with increased expression levelsBCL-3 in vitro by incubating either a GSK3 (positive
control) or a CKII recombinant protein with a GST-BCL-3 of the BCL-3 hypophosphorylated proteins (Figure 2B,
left upper panel, compare lanes 3–5 with lane 2). More-fusion protein. We did not detect any BCL-3 phosphory-
lation by CKII (Figure 1E, top panel). Moreover, the ki- over, when 293 cells were transfected with an expres-
sion vector coding for a BCL3 mutant lacking both GSK3nase Akt, which is known to phosphorylate and to inhibit
GSK3, did not phosphorylate BCL-3 in vitro, whereas phosphorylation sites (S394 and S398, and named
“BCL-3 MT S”) and treated with LiCl, this inhibitor hadErk1 did (Figure 1E, lower panel).
We transfected 293 cells with a GSK3 expression no effect on the BCL-3 MT S migration profile (Figure
2B, right upper panel, compare lanes 2 and 3). Similarly,vector and performed either an anti-HA (negative con-
trol) or an anti-GSK3 immunoprecipitation, and the re- exogenous expression of GSK3did not modify the BCL-3
MTS migration profile (lane 4). To investigate the effect ofsulting immunoprecipitates were used for an in vitro
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Figure 2. BCL-3 Is Phosphorylated by GSK3
(A) GSK3-mediated BCL-3 phosphorylation in
293 cells. Anti-HA (negative controls) or anti-
GSK3 immunoprecipitates from 293 cells
transfected with a GSK3 expression vector
were subjected to an in vitro kinase assay
using a purified GST-BCL-3 protein as sub-
strate.
(B and C) LiCl inhibits GSK3-mediated BCL-3
phosphorylation. (B) 293 cells were trans-
fected with pcDNA3 (left panels, lane 1), wild-
type FLAG-BCL-3 (left panels, lanes 2–5, and
right panels, lane 1), FLAG BCL-3 MT S (right
panels, lanes 2–4), and with GSK3 (right pan-
els, lane 4) and were left unstimulated (left
panels, lanes 1 and 2, and right panels, lanes
1, 2, and 4) or treated with increasing concen-
trations of LiCl, as indicated. Extracts were
subjected to anti-FLAG or GSK3 Western
blots (top and bottom panels, respectively).
(C) Karpas cells were left untreated (lane 1)
or incubated with LiCl for the indicated peri-
ods of time (lanes 2–5). Cell extracts were subjected to anti-BCL-3 and GSK3/ Western analysis.
(D) Endogenous BCL-3 and GSK3 proteins interact. Karpas cell extracts were immunoprecipitated with anti-HA or BCL-3 antibodies (lanes
1 and 2, respectively), and an anti-GSK3 Western blot was performed on the immunoprecipitates (top right panel). Extracts were subjected
to anti-GSK3 (top left panel) and BCL-3 Western analysis (bottom panel).
LiCl on endogenous BCL-3, we selected the Karpas cell MT S remained stable up to 4 hr of treatment (Figure
3A), suggesting that GSK3-mediated phosphorylationline, which highly expresses BCL-3 (Nishikori et al.,
2003). These cells were left untreated or stimulated from triggers BCL-3 degradation.
To determine whether BCL-3 is degraded through the1 to 6 hr with LiCl, and the status of GSK3-mediated
BCL-3 phosphorylation was assessed by Western analy- proteasome pathway, we assessed BCL-3 stability in
the presence of MG132, a proteasome inhibitor. 293sis (Figure 2C). BCL-3 appeared mostly hyperphosphor-
ylated in unstimulated cells (Figure 2C, upper panel, lane cells were transfected with a BCL-3 expression plasmid
and left unstimulated or treated with CHX and/or MG1321), but LiCl treatment led to severe decrease of the
BCL-3 phosphorylated forms, whereas the BCL-3 hypo- (Figure 3B). BCL-3 proteins were barely detectable after
4 hr of CHX treatment, as shown before (Figure 3B, thirdphosphorylated forms remained unchanged (Figure 2C,
upper panel, compare lane 1 with lanes 2–5). Taken lane), but pretreatment with MG132 prevented BCL-3
degradation (Figure 3B, upper panel, fourth lane). Wetogether, these results indicate that GSK3 phosphory-
lates BCL-3. The ability of GSK3 to interact with BCL-3 also noticed that MG132 alone enhanced BCL-3 expres-
sion (Figure 3B, upper panel, fifth lane), confirming thatwas investigated by coimmunoprecipitation experiments
in Karpas cells. Endogenous GSK3, but not GSK3, BCL-3 degradation occurs through the proteasome.
Because proteasome-mediated degradation followswas found in anti-BCL-3, but not in anti-HA, immunopre-
cipitates (Figure 2D, top right panel, lanes 2 and 1, re- protein ubiquitination on the lysine  amino group (Ben-
Neriah, 2002), we determined whether GSK3 triggersspectively). Therefore, GSK3 interacts and phosphory-
lates BCL-3 on S394 and S398. BCL-3 polyubiquitin linkage. 293 cells were transfected
with expression vectors coding for HA-ubiquitin and
FLAG-BCL-3 with or without increasing amounts of aGSK3-Mediated Phosphorylation Targets
BCL-3 Degradation GSK3 expression vector. Cells were treated with MG132
for 90 min, and anti-FLAG immunoprecipitations followedBCL-3 is a nuclear protein, unlike the other members of
the IB family. To determine whether GSK3-mediated by anti-HA Western analysis were carried out. GSK3dose-
dependent ubiquitin-conjugated BCL-3 adducts were de-BCL-3 phosphorylation regulates its cellular localization
as described for cyclin D1 (Diehl et al., 1998), BCL-3 tected in cells overexpressing both FLAG-BCL-3 and
GSK3 (Figure 3C, top panel, lanes 3 and 4), suggestingwild-type or MT S was expressed in 293 cells, and immu-
nofluorescence experiments showed that both ectopi- that this kinase indeed triggers BCL-3 polyubiquitina-
tion. To determine whether LiCl affected GSK3-medi-cally expressed proteins were found in the nucleus (data
not shown). Therefore, GSK3-mediated phosphorylation ated BCL-3 ubiquitination, 293 cells were transfected
with expression vectors for HA-Ub (Figure 3D, lanesdoes not regulate BCL-3 cellular localization.
Because GSK3-mediated phosphorylation triggers sub- 1–5), FLAG-BCL-3 (lanes 2–5), and GSK3 (lanes 4 and 5)
and subsequently treated with LiCl, as indicated (lanes 3sequent proteolysis of the substrate (Diehl et al., 1998;
Welcker et al., 2003), we investigated whether BCL-3 sta- and 5), followed by a 2 hr stimulation with MG132 (lanes
1–5). Anti-FLAG immunoprecipitations followed by anti-bility was modulated by GSK3 phosphorylation. 293 cells
were transfected either with the wild-type or MT S BCL-3 HA Western analysis were performed. Again, ubiquitin-
conjugated BCL-3 adducts were detected when BCL-3expression plasmids and subsequently treated with
cycloheximide (CHX). Wild-type BCL-3 protein levels de- and GSK3 were coexpressed (Figure 3D, upper panel,
compare lanes 1 and 4), and LiCl treatment decreasedcreased after 2 hr of treatment of CHX whereas BCL-3
Molecular Cell
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Figure 3. GSK3-Mediated BCL-3 Phosphorylation and Subsequent Degradation through Ubiquitin Linkage Is Inhibited by Akt
(A) The BCL-3 MT S is more stable than the wild-type BCL-3 protein. 293 cells transfected with either the wild-type BCL-3 or BCL-3 MT S
expression plasmid were treated with 50 g/ml cycloheximide (“CHX”) for the indicated times. An anti-BCL-3 Western blot was carried out
on the resulting extracts.
(B) BCL-3 degradation occurs through the proteasome pathway. 293 cells were transfected either with pcDNA3 (first lane) or with a BCL-3
expression vector (other lanes, as indicated). Cells were left unstimulated (second lane) or treated with CHX for 4 hr (third lane) or with MG132
for 30 min followed by CHX for 4 hr (fourth lane) or with MG132 alone for 4 hr (fifth lane), as indicated. An anti-BCL-3 Western blot (upper
panel) was carried out on the extracts. A nonspecific signal of the anti-BCL-3 Western blot (“ns”) was used for normalization.
(C) GSK3 triggers BCL-3 ubiquitin linkage. 293 cells were transfected either with HA-ubiquitin alone (lane 1) or with both HA-ubiquitin and
FLAG-BCL-3 (lane 2) or with a combination of HA-ubiquitin, FLAG-BCL-3, and increasing amounts of GSK3 (lanes 3 and 4). Cells were treated
for 90 min with MG132 prior to cell lysis, and anti-FLAG imunoprecipitations followed by anti-HA Western analysis were carried out on the
extracts (top panel). Anti-GSK3 and -BCL-3 Western blots were performed on the cell extracts as well (bottom panels), and a nonspecific
signal of the anti-BCL-3 Western blot (“ns”) was used for normalization.
(D) GSK3-mediated BCL-3 ubiquitination is inhibited by LiCl treatment in 293 cells, BCL-3-expressing MEFs, and Karpas cells (left, middle, and
right panels, respectively). On the left, 293 cells were transfected with HA-ubiquitin alone (lane 1) or with both HA-ubiquitin and FLAG-BCL-3 (lanes
2 and 3) or with a combination of HA-ubiquitin, FLAG-BCL-3, and GSK3 (lanes 4 and 5). Cells were left unstimulated (lanes 1, 2, and 4) or treated
with LiCl 50 mM for 2 hr (lanes 3 and 5) followed by a 2 hr treatment with MG132 (lanes 1–5). Anti-FLAG immunoprecipitations followed by anti-
HA Western analysis were carried out on the cell extracts. Anti-FLAG and anti-GSK3 Western blots were performed on the cell extracts.
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BCL-3 ubiquitination (Figure 3D, upper panel, compare GSK3-Mediated BCL-3 Phosphorylation Does Not
Affect Its Interaction with p50 and p52lanes 4 and 5). A slight decrease of BCL-3 ubiquitination
was also detected after LiCl treatment in the absence of As BCL-3 controls transcription through formation of
heterocomplexes with p50 or p52 (Bours et al., 1993:GSK3 overexpression (Figure 3D, upper panel, compare
lanes 2 and 3). An anti-BCL-3 Western blot on the ex- Franzoso et al., 1993; Fujita et al., 1993), we investigated
whether GSK3 regulates BCL-3’s ability to bind thesetracts again showed decreased BCL-3 phosphorylation
in the presence of LiCl (Figure 3D, middle panel, com- proteins and activate transcription from a B site. EMSA
experiments were carried out with nuclear extracts frompare lane 2 with lane 3 and lane 4 with lane 5). We next
investigated the effect of LiCl in MEF cells infected with 293 cells transfected with p52 either alone or in combi-
nation with wild-type BCL-3, BCL-3 MT S, or BCL-3 MTa retroviral vector expressing BCL-3 and in Karpas cells
(Figure 3D, middle and right panels, respectively) and K, a BCL-3 mutant with both lysines 13 and 26 mutated
to arginines. An NF-B binding activity was detected inalso observed that this GSK3 inhibitor led to a decrease
of BCL-3 ubiquitination (Figure 3D, in the middle, upper cells transfected with p52 alone, and this activity was
enhanced in a similar way in the presence of wild-typepanel, lane 2, and on the right, upper panel, compare
lanes 3 and 4 with lane 2). Therefore, LiCl decreased and mutant BCL-3 proteins (Figure 4A). Therefore,
GSK3-mediated phosphorylation does not appear toBCL-3 ubiquitination through inhibition of GSK3 in a
variety of cellular models. regulate the ability of the BCL-3/p52 heterocomplex to
bind DNA.BCL-3 harbors five lysine residues: two, K13 and K26,
in the N-terminal domain and three, K260, K310, and The transactivation potential of BCL-3 and its mutants
was investigated by performing luciferase assays, usingK330, within the ankyrin repeats (Figure 3E). To deter-
mine which residues are targeted for ubiquitination and a B reporter plasmid. When expressed alone, wild-type
BCL-3 as well as BCL-3 MT S and MT K barely inducedsubsequent BCL-3 degradation, wild-type BCL-3, BCL-3
MT S, or a BCL-3 mutant lacking the N-terminal 118 the luciferase activity, which was, however, strongly en-
hanced when p52 was coexpressed (Figure 4B, leftamino acids (N BCL-3) was expressed in 293 cells
together with an HA-ubiquitin expression plasmid (Fig- panel). Interestingly, the BCL-3 MT K/p52 complex sys-
tematically displayed reduced transactivation abilitiesure 3E, “	” lanes). N BCL-3 was reproducibly ex-
pressed at higher levels compared to wild-type BCL-3 compared to wild-type BCL-3 and BCL-3 MT S/p52
complexes (Figure 4B). The wild-type BCL-3/p50 com-but showed the same phosphorylation profile (Figure
3E, lower panels). Anti-BCL-3 immunoprecipitations fol- plexes transactivated less efficiently than the BCL-3/
p52 complexes, and this transactivation was not re-lowed by anti-HA Western blots showed BCL-3 polyubi-
quitination when both HA-Ub and wild-type BCL-3 were duced with the BCL-3 MT S and MT K mutants (Figure
4B, right panel). We next investigated whether BCL-3coexpressed (Figure 3E, “	” lanes). Polyubiquitination
was barely detectable with the BCL-3 MT S and was not phosphorylation regulated its ability to interact with p50
or p52. Extracts from 293 cells transfected with a p50detected after N BCL-3 expression (Figure 3E, upper
panels). These results suggest that GSK3-mediated or p52 expression plasmid in combination with wild-
type BCL-3, BCL-3 MT S, or BCL-3 MT K vectors wereBCL-3 phosphorylation triggers its subsequent degra-
dation through ubiquitin linkage on N-terminal lysine immunoprecipitated with anti-BCL-3 or HA (negative
control) antibodies, and anti-p50 or -p52 Western blotsresidues, presumably K13 and K26.
As GSK3 activation is inhibited by the Akt/PKB kinase were performed on the immunoprecipitates (Figures 4C
and 4D). In these conditions, p50 and p52 interacted(Cross et al., 1995), we investigated BCL-3 phosphoryla-
tion in 293 cells transfected with a retroviral construct with BCL-3 independently of the presence of the GSK3
phosphorylation sites and of the lysine residues (Figuresexpressing BCL-3-IRES-GFP with or without increasing
amounts of a constitutively activated Akt (Myr-Akt; Fig- 4C and 4D, upper panels). Taken together, these results
demonstrate that BCL-3’s ability to interact with p50ure 3F, lanes 2–5). Overexpression of Myr-Akt led to a
decrease of BCL-3 phosphorylation (Figure 3F, upper and p52 is not modulated by GSK3-mediated phosphor-
ylation.panel, compare lane 2 with lanes 3–5), whereas the
BCL-3 hypophosphorylated forms slightly increased.
GFP expression remained unchanged (data not shown). BCL-3 Interacts with HDAC1, -3, and -6
We previously demonstrated that IB interacts withTherefore, Akt activation prevents BCL-3 phosphoryla-
tion, presumably through GSK3 inhibition. HDAC1 and -3, but not with HDAC2, -4, -5, and -6 (Via-
In the middle, BCL-3-expressing MEF cell extracts were subjected to anti-BCL-3 immunoprecipitations followed by anti-ubiquitin Western
analysis (top panel). Anti-BCL-3 and GSK3 Western analysis on the cell extracts are shown (bottom panels). On the right, Karpas cells were
left unstimulated (lanes 1 and 2) or treated for 2 or 6 hr with LiCl (lanes 3 and 4, respectively) followed by a 2 hr treatment with MG132 (lanes
1–4). Cell extracts were subjected to an immunoprecipitation using either a preimmune serum (negative control, lane 1) or an anti-BCL-3
antibody (lanes 2–4) followed by an anti-Ub Western blot (upper panel). Extracts were subjected to anti-GSK3 and BCL-3 Western analysis
as well.
(E) Ubiquitination of wild-type BCL-3, but not BCL-3 mutants. Representation of the BCL-3 protein on the top. The ankyrin repeats are shown
as a hatched rectangle, whereas the lysine residues are represented by vertical bars. On the bottom, 293 cells were transfected with vectors
for wild-type BCL-3, BCL-3 MT S, orN-BCL-3 alone (
) or combination with HA-ubiquitin (	), and anti-BCL-3 immunoprecipitation experiments
followed by anti-HA Western blots were done on the extracts (upper panel). An anti-BCL-3 Western blot is illustrated at the bottom panel.
(F) Constitutively activated Akt inhibits constitutive BCL-3 phosphorylation. 293 cells were transfected with pcDNA3 (lane 1) or with a BCL-3-
IRES-GFP-expressing construct with or without (lane 2) increasing amounts of constitutively activated Akt (Myr-Akt, lanes 3–5). Anti-BCL-3,
anti-Akt, and anti-phospho Akt Western analyses were carried out on the extracts.
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Figure 4. BCL-3 Phosphorylation Does Not Affect DNA Binding, Transcriptional Activity, and Interaction with p50 and p52
(A) p52 enhanced DNA binding activities by wild-type and BCL-3 mutants. 293 cells were transfected with either pcDNA3, p52, or with a
combination of p52 and wild-type BCL-3, BCL-3 MT S, or BCL-3 MT K. EMSA were performed with the resulting nuclear extracts and a B probe.
(B) Transcription potential of the wild-type and BCL-3 mutants on a B reporter plasmid. 293 cells were transfected with 0.2 g of RSV-gal
and 0.5 g of the B reporter plasmid either alone or with 0.5 g of the indicated expression plasmid, and luciferase activities were measured.
The data from three independent experiments performed in triplicate after normalization with the -galactosidase activities of the extracts
are shown (mean values  SD).
(C and D) BCL-3 and its mutants interact in a similar way with p52 (C) or p50 (D). 293 cells were transfected with p52 (C) or p50 (D) and wild-
type BCL-3, BCL-3 MT S, or BCL-3 MT K, and anti-BCL-3 or -HA (negative control) immunoprecipitations followed by anti-p52 (C) or p50 (D)
Western blots (upper panels) were performed. The presence of p52, p50, and wild-type BCL-3 and mutants in the extracts is illustrated by
Western analysis (middle and lower panels).
tour et al., 2003b). As this interaction requires IB an- lated forms of wild-type BCL-3 and BCL-3 MT K were
predominant in the input, BCL-3 proteins in the immuno-kyrin repeats, we determined whether BCL-3 also inter-
acts with the HDAC proteins by detecting ectopicaly precipitates showed predominantly the hypophosphor-
ylated forms (Figure 5C, left and top panels, compareexpressed BCL-3 in the anti-FLAG immunoprecipitates
of cells transfected with BCL-3 and the FLAG-tagged lanes 2, 4, and 6 with the lower panel showing BCL-3
expression in the input). A similar observation was alsoHDAC vectors. BCL-3 associated with HDAC1 (Figure
5A, left and top panel, lane 2), HDAC3, and HDAC 6 made for HDAC3 and HDAC6 (Figure 5C, middle and
right panels on the top, respectively). Therefore, these(Figure 5A, top panel on the right, lanes 2 and 8, respec-
tively), but not with HDAC2 (Figure 5A, left and top panel, results suggest that GSK3-mediated BCL-3 phosphory-
lation modulates BCL-3 interaction with a subset oflane 4), -4, and -5 (Figure 5A, top panel on the right,
lanes 4 and 6, respectively). HDAC proteins.
To investigate whether GSK3-mediated BCL-3 phos-
phorylation regulates its interaction with these transcrip- GSK3-Mediated BCL-3 Phosphorylation
on S394/S398 Attenuates Its Oncogenicitytional repressors, FLAG-HDAC1 was cotransfected with
wild-type, BCL-3 MT S, or BCL-3 MT K expression vec- As BCL-3 overexpression has been associated with B
cell chronic lymphocytic leukaemia and because BCL-3tors, and anti-BCL-3 (or anti-HA as negative controls)
immunoprecipitations were performed prior to anti-FLAG is phosphorylated in lymphoma cells, we investigated
whether BCL-3’s transforming properties are regulatedWestern blots on the immunoprecipitates. All three
BCL-3 proteins associated with HDAC1 in a similar man- by GSK3-mediated phosphorylation. NIH3T3 cells stably
expressing the different BCL-3 forms were generated byner (Figure 5B, top panel). The reverse immunoprecipita-
tion was carried out by detecting BCL-3 in the anti-FLAG infection with either an empty retroviral vector (negative
control) or a retroviral construct expressing wild-typeimmunoprecipitates. As expected, HDAC1 associated
with all three BCL-3 proteins (Figure 5C, left and top BCL-3, MT S, MT K, or RasV12 (positive control). Cells
infected with the empty vector did not express BCL-3,panels, lanes 2, 4, and 6). While the hyperphosphory-
GSK3-Mediated BCL-3 Phosphorylation
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Figure 5. BCL-3 Interacts with HDAC1, -3,
and -6
(A) BCL-3 interacts with HDAC1, -3, and -6,
but not with HDAC2, -4, and -5. 293 cells were
transfected with a BCL-3 expression vector
either alone (left and right panels, odd lanes)
or together with FLAG-tagged HDAC1, -2 (left
panels, even lanes), -3, -4, -5, or -6 (right pan-
els, even lanes) vectors, and anti-FLAG im-
munoprecipitations followed by anti-BCL-3
Western analysis were performed on the cell
extracts (upper panels). The presence of
BCL-3 and FLAG-tagged HDAC proteins in
the cell extracts is illustrated by Western
analysis using the corresponding antibodies
(middle and lower panels).
(B) BCL-3 and its mutants interact with
HDAC1. 293 cells were transfected with vec-
tors for FLAG-HDAC1 and wild-type BCL-3,
BCL-3 MT S, or BCL-3 MT K. Anti-BCL3 or
anti-HA (negative control) immunoprecipita-
tions followed by anti-FLAG Western blots
were done on the extracts (upper panel). The
presence of BCL-3 and FLAG-tagged HDAC1
in the cell extracts is illustrated by Western
blots using the corresponding antibodies
(lower and middle panels).
(C) Hypophosphorylated forms of BCL-3 pref-
erentially interact with HDAC1, -3, and -6. 293
cells were transfected with FLAG-HDAC1, -3,
or -6 (left, middle and right panels, respec-
tively) and wild-type BCL-3 (lanes 1 and 2),
BCL-3 MT S (lanes 3 and 4), or BCL-3 MT K
(lanes 5 and 6) expression vectors, and anti-
FLAG immunoprecipitations were carried out
followed by anti-BCL-3 Western analysis on
the cell extracts (upper panels). An anti-BCL-3
Western blot performed on the cell lysates is
shown (lower panel). The presence of HDAC1,
-3, and -6 is illustrated by Western analysis
performed with anti-HDAC1, -3, or FLAG anti-
bodies, respectively (middle panels).
while the cells infected with the BCL-3 retroviral con- type BCL-3-expressing cells had significant tumor for-
mation. While that ratio was not significantly differentstructs did (Figure 6A).
The proliferation of the NIH3T3 cells expressing BCL-3 in mice injected with BCL-3 MT K-expressing cells (three
out of eight), six out of eight mice injected with BCL-3or its mutant forms was evaluated. Wild-type BCL-3-
expressing cells proliferated slightly faster than the cells MT S-expressing cells developed tumors. These results
show that BCL-3 is able to induce tumor growth in vivo.infected with the empty vector or the BCL-3 MT K, while
the proliferation rate of the BCL-3 MT S cells turned out Moreover, this oncogenic potential was enhanced by
mutations of the GSK3 phosphorylation sites.to be significantly higher (Figure 6B). Therefore, BCL-3
overexpression enhances NIH3T3 proliferation, and GSK3-
mediated phosphorylation attenuates this effect. GSK3-Dependent BCL-3 Phosphorylation Regulates
the Expression of Some BCL-3 Target GenesThe BCL-3 oncogenicity in NIH3T3 cells was further
assessed in vitro by foci formation assays. Cells infected As mutation of both GSK3 phosphorylation sites en-
hanced BCL-3 oncogenicity, we performed microarraywith an empty vector developed only a few isolated foci,
while wild-type BCL-3-expressing cells generated a high analysis in order to identify genes differentially regulated
by wild-type BCL-3 versus BCL-3 MT S and BCL-3 MT K.number of them (Figure 6C). Strikingly, foci number was
further increased in BCL-3 MT S-expressing cells. Foci Total RNAs extracted from NIH3T3 cells stably infected
with either an empty retroviral vector, the wild-typewere not more numerous in BCL-3 MT K-expressing
cells, but their size was increased compared to wild- BCL-3, BCL-3 MT S, or BCL-3 MT K mutants were sub-
mitted to microarray analysis. The transcription of astype BCL-3-expressing cells (Figure 6C).
The same infected NIH3T3 cells were injected in the many as 50 genes were induced in NIH3T3 cells overex-
pressing BCL-3 by comparison with control cells. Sur-flank of nude mice, and tumor development was moni-
tored for 3 weeks (Figure 6D). Injection of RasV12- prisingly, despite a more pronounced oncogenic poten-
tial, BCL-3 MT S regulated most of these target genesexpressing cells led to massive tumor development as
expected. While none of the negative control cells gen- similarly compared to wild-type BCL-3. Only four of
these genes showed different regulation between wild-erated tumors, two out of eight mice injected with wild-
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Figure 6. BCL-3 and Its Mutants Are Oncogenic In Vitro and In Vivo
(A) Expression of wild-type BCL-3, BCL-3 MT S, and BCL-3 MT K in NIH3T3 infected with the corresponding retroviral constructs.
(B) BCL-3 MT S has an enhanced proliferative phenotype compared to wild-type BCL-3, BCL-3 MT K, and cells infected with the empty
vector. A growth curve was established for NIH3T3 cells infected with the indicated retroviral construct by counting the number of cells every
2 days for 11 days.
(C) Foci formation assays with NIH3T3 cells infected with the empty vector (top dish on the left) or with the BCL-3 vector or its mutants, as
indicated. Cells infected with RasV12 were used as a positive control to visualize the foci formation after coloration with Giemsa.
(D) Wild-type BCL-3 and its mutant are oncogenic in vivo. NIH3T3 cells infected with the indicated retroviral constructs were subcutaneously
injected in nude mice. Tumor formation was evaluated for three weeks after the injection.
type and BCL-3 MT S-expressing cells: SLPI (2-fold in- a new GSK3 substrate. First, BCL-3 is phosphorylated
duction in MT S cells), Cxcl1 (2-fold induction in MT S by this kinase in vitro on GSK3 consensus residues.
cells), IFI205 (2.3-fold induction in MT S cells), and CYPIBI While most GSK3 substrates require a primo phosphory-
(2-fold repression in MT S cells). Real-time PCR experi- lation, we could not identify any priming kinase for
ments confirmed this expression profile in wild-type and BCL-3. Indeed, CKII, which often acts as the priming
MT S cells (Figure 7B, upper panels). On the other hand, kinase, does not phosphorylate BCL-3. However, previ-
BCL-3 MT K expression modified the expression of only ous work showed that this primo phosphorylation is
13 genes compared to control cells, suggesting that dispensable when a proline residue is present down-
lysines 13 and 26 are critical for BCL-3 transactivation stream of the targeted residues and when GSK3 inter-
potential. The expression of these 13 candidates, acts with its substrate, as this is the case for BCL-3. As
namely the genes coding for pleiotrophin, Serpin B1A, additional evidence for GSK3 acting as a BCL-3 kinase,
collagen 5A1, IdB2, BmP1, Actin, Tbx14, Cyclin G2, Ppic LiCl, a specific GSK3 inhibitor, prevents constitutive
1, collagen 8A1, and Rgs 16, is regulated by wild-type BCL-3 phosphorylation and subsequent ubiquitination
BCL-3, and mutants and can thus be considered suffi- in a variety of cellular models including 293 cells, MEFs,
cient to induce cell transformation (Figure 7A). The ex- and Karpas cells. Interestingly, mutation of both GSK3
pression profile of three of these genes (pleiotrophin, phosphorylation sites completely abolished constitutive
serpin B1A, and IdB2) was also confirmed by real-time BCL-3 phosphorylation, therefore indicating that GSK3
PCR experiments (Figure 7B, lower panels). is the main kinase that constitutively phosphorylates
BCL-3. We also show that endogenous GSK3, but not
GSK3, interacts with BCL-3, which does not rule outDiscussion
the possibility that both kinases phosphorylate BCL-3
in vivo. In any case, GSK3 can compensate the lossIn this report, we identified GSK3 as a BCL-3 kinase
of GSK3 for BCL-3 phosphorylation since this onco-and demonstrated that this phosphorylation critically
protein was still constitutively phosphorylated in MEFmodulates BCL-3 function by triggering its degradation
cells KO for GSK3 (data not shown).by modulating its oncogenicity and by selectively regu-
GSK3-mediated BCL-3 phosphorylation is constitu-lating a subset of newly identified BCL-3 target genes.
We provided several lines of evidence for BCL-3 being tive and targets its subsequent degradation through ubi-
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Figure 7. Phosphorylation-Dependent Reg-
ulation of a Subset of Newly Identified BCL-3
Target Genes
(A) Microarray analyses were carried out us-
ing RNAs extracted from NIH3T3 cells in-
fected with the indicated retroviral con-
structs. The identity of the BCL-3 target
genes as well as the intensity of their induc-
tion or their repression in the BCL-3 express-
ing cells (fold induction) and the p values are
mentioned. The level of expression in control
cells is set to 1.
(B) Expression of selected BCL-3 target
genes. RNA was extracted from infected
NIH3T3 cells, and gene expression was mea-
sured by real-time PCR. The transcript copy
number for the most abundant population is
set to 100%. Control corresponds to the
NIH3T3 cells stably infected with the empty
retroviral construct, whereas “WT,” “MT S,”
and “MT K” correspond to the NIH3T3 cells
stably infected with the wild-type, the MT S,
or the MT K BCL-3 expressing retrovirus, re-
spectively. The data were normalized by
quantification of the GAPDH transcripts.
quitin linkage and proteasome decay. GSK3-mediated analysis is in favor of this hypothesis, at least for some
BCL-3 target genes such as SLPI (see below).substrate degradation (Frame and Cohen, 2001) has al-
ready been described for cyclin D1 (Diehl et al., 1998) We noticed that the BCL-3 MT K that is no longer
ubiquitinated had a decreased transactivation effect.and cyclin E (Welcker et al., 2003). As BCL-3 is onco-
genic, this mechanism may represent a way to control Interestingly, both targeted lysine residues are within
one BCL-3 transactivation domain (Bours et al., 1993).BCL-3 levels in normal cells. Any translocation that causes
BCL-3 overexpression may then overcome GSK3-medi- Several studies demonstrated that some DNA-bound
transactivation factors are targeted for ubiquitinationated BCL-3 phosphorylation and degradation.
BCL-3 has been described as a transcriptional activa- within their transactivation domain and this signal is
required for transcriptional activation (Conaway et al.,tor (Bours et al., 1993; Fujita et al., 1993). Therefore, BCL-3
presumably recruits coactivator complexes and/or re- 2002; Freiman and Tjian, 2003). Therefore, there may
be a link between BCL-3 ubiquitination and activation.moves corepressors such as the HDAC proteins from
the promoter vicinity to activate transcription (Baek et Alternatively, the same lysine residues could also be
targeted for acetylation, a posttranslational modificational., 2002). We identified three HDAC proteins, namely
HDAC1, -3, and -6, that interact with BCL-3. Although associated with transcriptional activation (Freiman and
Tjian, 2003), although we have no evidence for BCL-3both hypophosphorylated and phosphorylated forms of
BCL-3 were found associated with the HDAC proteins, being acetylated so far (data not shown). In any case,
both lysine residues appear to be critical for optimalwe noticed that hypophosphorylated BCL-3 preferen-
tially interacted with the HDACs. As BCL-3 has been BCL-3 mediated transcription since many BCL-3 target
genes that we identified here (see below) were not in-described as a transcriptional activator (Bours et al.,
1993), the hypophosphorylated forms of BCL-3 could duced in NIH3T3 cells overexpressing the BCL-3 MT K.
This paper demonstrates that BCL-3 can directlymore efficiently remove corepressors such as the HDAC
proteins from the promoters and therefore better acti- transform cells in vitro. By comparing transformation by
wild-type and mutated BCL-3, we observed that all threevate some target genes expression. Our microarray
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ated by PCR using the corresponding wild-type or BCL-3 mutantsforms are transforming, but mutation of S394 and S398
cloned into the pMT2T vector as templates (Bours et al., 1993).significantly enhanced BCL-3 oncogenic potential. The
The GST-BCL-3 fusion construct was generated by subcloning therole of GSK3 in the modulation of BCL-3 oncogenicity
BCL-3 coding sequence into the pGEX 6P-3 plasmid (Amersham
is strongly suggested by our data since we show that Pharmacia Biotech, Uppsala, Sweden). The wild-type BCL-3, BCL-3
GSK3 is the main BCL-3 kinase and phosphorylates this MT S, and MT K coding sequences were subcloned into the pBabe
puromycin retrovirus as was the wild-type BCL-3 sequence into theoncoprotein in various cell types including the karpas
IRES GFP MSCV retroviral vector. The RasV12 pbabe puro wascells, which are derived from an anaplastic large cell
previously described (Ferbeyre et al., 2002). The GSK3 expressionlymphoma. Because we also show that Akt inhibits
vector was generated by PCR amplifying and subcloning the GSK3BCL-3 phosphorylation, it is tempting to speculate that
coding sequence from a human Marathon cDNA library (Clontech,
constitutive Akt activation, a hallmark of many trans- Palo Alto, CA) into the pcDNA5 vector (Invitrogen, Carlsbad, CA).
formed cells, attenuates BCL-3 phosphorylation and its The HA-ubiquitin and Myr-Akt expression vectors were gifts from
C. van Lint (Free University of Brussels, Belgium) and Y-C. Liu (LIAI,subsequent degradation, thus enhancing BCL-3 onco-
San Diego, CA), respectively.genicity.
Very few BCL-3 target genes have been characterized
Bioinformatics, Kinase Assays, Site-Directed Mutagenesis,so far (Westerheide et al., 2001; Elliott et al., 2002). We
and Immunoprecipitationsidentified fifty new BCL-3 target genes. Many of them
Potential BCL-3 phosphoacceptor sites were searched by submit-are known to play critical roles in oncogenesis, and
ting the human BCL-3 primary amino acid sequence to the Scansite
some of them have already been described as NF-B (http://scansite.mit.edu/) (Yaffe et al., 2001).
target genes (data not shown). Most of the identified For kinase assays, GST-BCL-3 fusion protein was expressed and
purified as described (Chariot et al., 1999) and incubated with aBCL-3 target genes were similarly induced in cells in-
recombinant CKII kinase or increasing amounts of the recombinantfected with wild-type or MT S BCL-3, indicating that
GSK3 kinase for 30 min at 30C as described (Leonardi et al., 2000).GSK3-mediated BCL-3 phosphorylation does not mod-
For site mutagenesis, BCL-3 pMT2T was used as template toulate the expression of most of its target genes. A few
generate BCL-3 mutants, using the QuikChange Site-Directed Muta-
target genes are however sensitive to BCL-3 phosphory- genesis Kit (Stratagene, La Jolla, CA). All the BCL-3 mutants were se-
lation and include SLPI (Devoogdt et al., 2003), Cxcl1, quenced.
Immunoprecipitations were performed as described (Viatour etCYPIBI, and IFI205. SLPI has already been described
al., 2003b).as an NF-B target gene in pre-B cells, but its expression
is decreased by NF-B (Li et al., 2001). SLPI is strongly
Nuclear Protein Extraction, Electrophoretic Mobilityinduced in BCL-3-overexpressing cells, and its level of
Shift Assay, and Reporter Assaysexpression is further enhanced in cells overexpressing
293 cells were transfected with the indicated expression vectors,BCL-3 MT S. Therefore, it is tempting to speculate that
and nuclear extracts as well as electrophoretic mobility shift assays
SLPI overexpression participates in BCL-3 oncogenic- (EMSA) were performed as previously described (Bentires-Alj et al.,
ity. Indeed, SLPI promotes in vivo tumor formation by 1999). Luciferase asssays were carried out as described (Leonardi
et al., 2000).Lewis lung carcinoma cells (Devoogdt et al., 2003). Cxcl1
has also been described as an NF-B target gene in
melanoma cells (Wood and Richmond, 1995). As BCL-3 Retroviral Transduction, Growth Curve, Foci Formation,
and Nude Mice Injectionmodifies Cxcl1 expression, multiple NF-B proteins can
Retroviral infection of NIH3T3 cells was performed according topossibly transactivate this target gene.
instructions from Dr. Nolan’s laboratory (http://www.stanford.edu/In conclusion, our data indicate that GSK3 constitu-
group/nolan/retroviral_systems/retsys.html).
tively phosphorylates BCL-3 and triggers its degrada- 20  103 cells were seeded in 12-well plates and counted every
tion. This phosphorylation limits BCL-3 oncogenicity, 2 days, starting 24 hr after plating. Medium was changed every
2 days. Each condition was plated and counted in triplicate. Theprobably by reducing BCL-3 lifespan and by limiting the
curves show a representative experiment out of three.transcription of a subset of BCL-3 target genes.
For foci assays, 1.5  106 infected NIH3T3 cells were seeded in
a 10 cm plate, and media was changed every 3 days. The cell
Experimental Procedures cultures were followed for 3 weeks, and colonies were visualized
with Giemsa staining.
Cell Culture, Biological Reagents, and Treatments For subcutaneous injection in nude mice, 106 cells were resus-
MEFs, 293, and NIH3T3 cells were maintained in DMEM supple- pended in 200 l of PBS and injected in the flank of 5-week-old
mented with 10% fetal calf serum (Life Technologies, Grand Island, nude mice (Swiss strain). Evaluation of tumor growth was performed
NY) and antibiotics. The Karpas 299 cell line was a gift from Dr. twice weekly and stopped after 3 weeks when mice injected with
F. Lambert (Laboratory of Human Genetics, University of Liege, RasV12 cells were sacrificed for ethical reasons.
Belgium) and was cultured in RPMI supplemented with 10% fetal
calf serum and antibiotics. Polyclonal anti-HA, anti-HDAC1, anti-
Affymetrix Microarray AnalysisHDAC3, anti-BCL-3, and monoclonal anti-ubiquitin antibodies were
Total RNAs were extracted from NIH3T3 cells stably infected withpurchased from Santa Cruz Biotechnologies (Santa Cruz, CA). Anti-
empty virus or virus expressing either wild-type BCL-3, BCL-3 MTAkt and anti-phospho Ser 473 Akt antibodies were obtained from
S, or BCL-3 MT K. The integrity of the RNAs was checked using theICN (Costa Mesa, CA) and Cell Signaling (Beverly, MA), respectively.
Agilent platform (Agilent 2100 Bioanalyzer). Biotin-labeled cRNA andAnti-FLAG antibodies and beads as well as recombinant GSK3
subsequent hybridization and scanning were performed followingprotein were purchased from Sigma (Sigma, St Louis, MO), whereas
the manufacturer’s instructions.recombinant Akt and Erk1 were obtained from Biosource (Camarillo,
CA) and Calbiochem (San Diego, CA), respectively.
The FLAG-HDAC1, -2, -3, -4, -5, and -6 constructs were previously Real-Time PCR
Real-time PCR was carried out using the TaqMan platform, as de-described (Viatour et al., 2003b) as were the BCL-3, p50, and p52
pMT2T expression vectors (Bours et al., 1992, 1993) and the N scribed (Heid et al., 1996), and primers, whose sequences are avail-
able upon request, were designed using the Primers ExpressBCL-3 pMT2T construct which lacks amino acids 1–119 of BCL-3
(Bours et al., 1993). The FLAG-tagged BCL-3 constructs were gener- software.
GSK3-Mediated BCL-3 Phosphorylation
45
Acknowledgments Franzoso, G., Bours, V., Azarenko, V., Park, S., Tomita-Yamaguchi,
M., Kanno, T., Brown, K., and Siebenlist, U. (1993). The oncoprotein
BCL-3 can facilitate NF-kappa B-mediated transactivation by re-The authors are grateful to C. van Lint and Y-C. Liu for the gifts
of plasmids. M.-P.M., A.C., and J.P. are Research Associates and moving inhibiting p50 homodimers from select kappa B sites. EMBO
J. 12, 3893–3901.Research Director, respectively at the Belgian National Fund for
Research (F.N.R.S.). This paper is dedicated to the memory of Freiman, R.N., and Tjian, R. (2003). Regulating the regulators: lysine
J. Gielen. This work was supported by grants from the TELEVIE, modifications make their mark. Cell 112, 11–17.
the Centre Anti-Cance´reux, IAP5/12, and the Belgian Federation Fujita, T., Nolan, G.P., Liou, H.C., Scott, M.L., and Baltimore, D.
against Cancer. E.D. was supported by a grant from the Arthritis (1993). The candidate proto-oncogene BCL-3 encodes a transcrip-
National Research Foundation (ANRF). tional coactivator that activates through NF-kappa B p50 homodi-
mers. Genes Dev. 7, 1354–1363.
Received: March 31, 2004
Heid, C.A., Stevens, J., Livak, K.J., and Williams, P.M. (1996). RealRevised: July 14, 2004
time quantitative PCR. Genome Res. 6, 986–994.Accepted: July 28, 2004
Karin, M., Cao, Y., Greten, F.R., and Li, Z.W. (2002). NF-kappaB inPublished: October 8, 2004
cancer: from innocent bystander to major culprit. Nat. Rev. Cancer
2, 301–310.References
Leonardi, A., Chariot, A., Claudio, E., Cunningham, K., and Sieben-
list, U. (2000). CIKS, a connection to IB-kinase and stress-activatedBaek, S.H., Ohgi, K.A., Rose, D.W., Koo, E.H., Glass, C.K., and Ro-
protein kinase. Proc. Natl. Acad. Sci. USA 97, 10494–10499.senfeld, M. (2002). Exchange of N-CoR corepressor and Tip60 co-
activator complexes links gene expression by NF-B and -amyloid Li, J., Peet, G.W., Balzarano, D., Li, X., Massa, P., Barton, R.W., and
precursor protein. Cell 110, 55–67. Marcu, K.B. (2001). Novel NEMO/IkappaB kinase and NF-kappa B
target genes at the pre-B to immature B cell transition. J. Biol. Chem.Ben-Neriah, Y. (2002). Regulatory functions of ubiquitination in the
276, 18579–18590.immune system. Nat. Immunol. 3, 20–26.
McKeithan, T.W., Rowley, J.D., Shows, T.B., and Diaz, M.O. (1987).Bentires-Alj, M., Hellin, A.C., Ameyar, M., Chouaib, S., Merville, M.P.,
Cloning of the chromosome translocation breakpoint junction of theand Bours, V. (1999). Stable inhibition of nuclear factor kappaB in
t(14;19) in chronic lymphocytic leukemia. Proc. Natl. Acad. Sci. USAcancer cells does not increase sensitivity to cytotoxic drugs. Cancer
84, 9257–9260.Res. 59, 811–815.
Nishikori, M., Maesako, Y., Ueda, C., Kurata, M., Uchiyama, T., andBours, V., Burd, P.R., Brown, K., Villalobos, J., Park, S., Ryseck, R.-P.,
Ohno, H. (2003). High-level expression of BCL3 differentiatesBravo, R., Kelly, K., and Siebenlist, U. (1992). A novel mitogen-
t(2;5)(p23;q35)-positive anaplastic large cell lymphoma from Hodg-inducible gene product related to p50/p105-NF-B participates in
kin disease. Blood 101, 2789–2796.transactivation through a B site. Mol. Cell. Biol. 12, 685–695.
Nolan, G.P., Fujita, T., Bhatia, K., Huppi, C., Liou, H.-C., Scott, M.L.,Bours, V., Franzoso, G., Azarenko, V., Park, S., Kanno, T., Brown,
and Baltimore, D. (1993). The BCL-3 proto-oncogene encodes aK., and Siebenlist, U. (1993). The oncoprotein BCL-3 directly trans-
nuclear IB-like molecule that preferentially interacts with NF-Bactivates through B motifs via association with DNA-binding p50B
p50 and p52 in a phosphorylation-dependent manner. Mol. Cell.homodimers. Cell 72, 729–739.
Biol. 13, 3557–3566.Bundy, D.L., and McKeithan, T.W. (1997). Diverse effects of BCL3
Ohno, H., Takimoto, G., and McKeithan, T.W. (1990). The candidatephosphorylation on its modulation of NF-B p52 homodimer binding
proto-oncogene BCL-3 is related to genes implicated in cell lineageto DNA. J. Biol. Chem. 272, 33132–33139.
determination and cell cycle control. Cell 60, 991–999.
Chariot, A., Princen, F., Gielen, J., Merville, M.-P., Franzoso, G.,
Viatour, P., Bentires-Alj, M., Chariot, A., Deregowski, V., de Leval,Brown, K., Siebenlist, U., and Bours, V. (1999). IB- enhances trans-
L., Merville, M.P., and Bours, V. (2003a). NF-kappa B2/p100 inducesactivation by the HOXB7 homeodomain-containing protein. J. Biol.
Bcl-2 expression. Leukemia 17, 1349–1356.Chem. 274, 5318–5325.
Viatour, P., Legrand-Poels, S., van Lint, C., Warnier, M., Merville,Cogswell, P.C., Guttridge, D.C., Funkhouser, W.K., and Baldwin,
M.-P., Gielen, J., Piette, J., Bours, V., and Chariot, A. (2003b). Cyto-A.S., Jr. (2000). Selective activation of NF-kappa B subunits in hu-
plasmic IB increases NF-B-independent transcription throughman breast cancer: potential roles for NF-kappa B2/p52 and for
binding to HDAC1 and HDAC3. J. Biol. Chem. 278, 46541–46548.BCL-3. Oncogene 19, 1123–1131.
Welcker, M., Singer, J., Loeb, K.R., Grim, J., Bloecher, A., Gurien-Conaway, R.C., Brower, C.S., and Conaway, J.W. (2002). Emerging
West, M., Clurman, B.E., and Roberts, J.M. (2003). Multisite phos-roles of ubiquitin in transcription regulation. Science 296, 1254–
phorylation by Cdk2 and GSK3 controls cyclin E degradation. Mol.1258.
Cell 12, 381–392.
Cross, D.A., Alessi, D.R., Cohen, P., Andjelkovich, M., and Hem-
Westerheide, S.D., Mayo, M.W., Anest, V., Hanson, J.L., and Bald-mings, B.A. (1995). Inhibition of glycogen synthase kinase-3 by insu-
win, A.S., Jr. (2001). The putative oncoprotein BCL-3 induces cyclinlin mediated by protein kinase B. Nature 378, 785–789.
D1 to stimulate G1 transition. Mol. Cell. Biol. 21, 8428–8436.Devoogdt, N., Hassanzadeh Ghassabeh, G., Zhang, J., Brys, L., De
Wood, L.D., and Richmond, A. (1995). Constitutive and cytokine-Baetselier, P., and Revets, H. (2003). Secretory leukocyte protease
induced expression of the melano growth stimulatory activity/GROinhibitor promotes the tumorigenic and metastatic potential of can-
alpha gene requires both NF-kappaB and novel constitutive factors.cer cells. Proc. Natl. Acad. Sci. USA 100, 5778–5782.
J. Biol. Chem. 270, 30619–30626.
Diehl, J.A., Cheng, M., Roussel, M.F., and Sherr, C.J. (1998). Glyco-
Yaffe, M.B., Leparc, G.G., Lai, J., Obata, T., Volinia, S., and Cantley,gen synthase kinase-3 regulates cyclin D1 proteolysis and subcel-
L.C. (2001). A motif-based profile scanning approach for genome-lular localization. Genes Dev. 12, 3499–3511.
wide prediction of signaling pathways. Nat. Biotechnol. 19, 348–353.
Elliott, S.F., Coon, C.I., Hays, E., Stadheim, T.A., and Vincenti, M.P.
(2002). Bcl-3 is an interleukin-1-responsive gene in chondrocytes
and synovial fibroblasts that activates transcription of the matrix
metalloproteinase 1 gene. Arthritis Rheum. 46, 3230–3239.
Ferbeyre, G., de Stanchina, E., Lin, A.W., Querido, E., McCurrach,
M.E., Hannon, G.J., and Lowe, S.W. (2002). Oncogenic ras and p53
cooperate to induce cellular senescence. Mol. Cell. Biol. 22, 3497–
3508.
Frame, S., and Cohen, P. (2001). GSK3 takes centre stage more
than 20 years after its discovery. Biochem. J. 359, 1–16.
